新闻
SIOX
--
0.00%
--
FCEL、INFI 和 SIOX 是上市前的赢家
ION Geophysical (NYSE:IO) +45% sees Q3 revenues more than doubling Q/Q Valneva SE (NASDAQ:VALN) +36% after topline results from late-stage VLA2001 COVID-19 trial Adamis Pharmaceuticals (NASDAQ:ADMP) +35% after FDA approves opioid overdose treatment ZIMHI M...
Seekingalpha · 11小时前
镰状细胞疾病药物市场将以高复合年增长率增长——2030 年全球行业分析、主要制造商和需求分析
Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and by region.
AmericaNewsHour · 15小时前
下周的催化剂观察:苹果事件、特斯拉收益、WeWork SPAC 和收益激增
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 3天前
更新:Sio Gene Therapies 将在 2021 年欧洲基因和细胞治疗学会虚拟大会上展示新数据
Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosisNEW YORK, and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (...
GlobeNewswire · 10/04 13:04
ADVM、SELB 和 OSUR 是上市前的赢家
Xenon Pharmaceuticals XENE +90% on positive XEN1101 data in mid-stage focal epilepsy study Elmira Savings Bank ESBK +66% Community Bank System to buy Elmira Savings Bank in $82.8M all cash deal OpGen OPGN +30% after announcing
Seekingalpha · 10/04 12:22
Sio Gene Therapies 将在 2021 年欧洲基因和细胞治疗学会虚拟大会上展示新数据
Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present new
Benzinga · 10/04 11:35
Sio Gene Therapies 将在 2021 年欧洲基因和细胞治疗虚拟大会上展示新数据
Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosisNEW YORK and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (N...
GlobeNewswire · 10/04 11:30
Sio Gene Therapies 将参加即将举行的会议
Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor ...
GlobeNewswire · 09/23 11:30
Tay-Sachs 疾病药物市场-销售展望、最新发展数据和 2030 年市场趋势预测
Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region.
AmericaNewsHour · 09/20 11:29
镰状细胞病药物市场:到 2030 年的行业展望、分类、需求、区域分析和预测
Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and by region.
AmericaNewsHour · 09/16 06:17
去年有不少内部人士投资了 Sio Gene Therapies Inc.(纳斯达克股票代码:SIOX),这对股东来说是个好消息
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 09/13 16:16
Sio Gene Therapies 宣布在 AXO-AAV-GM1 基因治疗的第 1/2 期研究中对首例 GM1 神经节苷脂沉积症早期婴儿患者进行给药
Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced dosing of the first Type
Benzinga · 09/09 11:20
Sio Gene Therapies 宣布在 AXO-AAV-GM1 基因治疗正在进行的 1/2 期研究中为首例 GM1 神经节苷脂沉积症早期婴儿(I 型)患者给药
- Study has now enrolled a total of nine patients across low-dose and high-dose cohorts- On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1 cohort in October 2021 NEW YORK, and DURHAM, N.C., Sept. 09,...
GlobeNewswire · 09/09 11:00
Sio Gene Therapies 在 AXO-AAV-GM1 基因治疗研究的低剂量队列中对第一个患者给药;股价上涨前贝尔
MT Newswires · 09/09 08:15
SVB Leerink 在 Sio 基因疗法方面保持跑赢大盘,将目标价下调至 6 美元
SVB Leerink analyst Mani Foroohar maintains Sio Gene Therapies (NASDAQ:SIOX) with a Outperform and lowers the price target from $7 to $6.
Benzinga · 08/12 16:09
BRIEF-Sio Gene Therapies Q1 Loss Per Share $0.16
reuters.com · 08/12 11:38
Sio Gene Therapies 第一季度每股收益为 (0.16) 美元,同比增长 (0.20) 美元
Sio Gene Therapies (NASDAQ:SIOX) reported quarterly losses of $(0.16) per share. This is a 20 percent increase over losses of $(0.20) per share from the same period last year.
Benzinga · 08/12 11:33
周二触及 52 周低点的股票
    Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows.
Benzinga · 08/10 14:05
周一触及 52 周低点的股票
    Monday morning, 34 companies reached new 52-week lows.
Benzinga · 08/02 14:01
机构拥有多少 Sio Gene Therapies Inc.(纳斯达克股票代码:SIOX)股票?
A look at the shareholders of Sio Gene Therapies Inc. ( NASDAQ:SIOX ) can tell us which group is most powerful...
Simply Wall St. · 07/13 10:46
微牛提供丰富的实时SIOX股票新闻,让你可以通过多个平台了解SIOX股票行情最新动态,这些免费的Sio Gene Therapies Inc新闻可以帮助你做出明智投资。
SIOX 简况
Sio Gene Therapies Inc是一家临床阶段的公司。该公司专注于开发神经退行性疾病的基因疗法。该公司正在开发一系列候选产品,用于治疗这些使人衰弱的疾病,包括GM1神经节苷脂贮积症、GM2神经节苷脂贮积症,包括Tay-Sachs和Sandhoff疾病以及帕金森病。该公司开展三个临床阶段项目,AXO-AAV-GM1、AXO-AAV-GM2和 AXO-Lenti-PD。AXO-AAV-GM1项目用于治疗GM1神经节苷脂沉积症。该项目利用腺相关病毒(AAV)载体传递GLB1基因的功能复制。AXO-AAV-GM2 项目用于治疗GM2神经节苷脂病,包括Tay-Sachs和 Sandhoff疾病。AXO-AAV-GM2项目利用双AAV载体传递HEXA基因和HEXB基因的功能复制。用于治疗帕金森病的AXO-Lenti-PD项目,包括ProSavin 0.5期研究。